Aspergillus Galactomannan Antigen by EIA
| Order Code: | GALACMAN |
| Epic Lab Code: | LAB2640 |
| Order Form: | A-1a Miscellaneous Request or Epic Req |
Commercial Mail-out Laboratory
6240 RCP
356-3527
6240 RCP
356-3527
Specimen:
Serum
Minimum:
1-3 mL serum
- OR -
1-3 mL BAL (bronc lavage) in sterile screw top tube
Rejection Criteria:
Lipemic, icteric, or hemolyzed specimens. Specimens that have
been stored at ambient temperature. Specimens that have been stored at
2-8°C for >5 days. If storage longer than 5 days is needed,
samples should be frozen at -70°C. Unless indicated as stored
frozen, the specimen will be rejected if the draw date is >5 days from
receipt at reference laboratory.
Analytic Time:
24 hours upon receipt at reference laboratory
Reference Range:
The reference range is an index of <0.5. Numerical index values will
bereported.
Patients with an index of ≥ 0.5 are considered to be positive
for galactomannan antigen.
Patients with an index of <0.5 are considered to be negative for
galactomannan antigen.
Specimens testing positive will be retested to confirm the positive
result.
Comments:
The Aspergillus Galactomannan EIA is a test, when used in conjunction
with other diagnostic procedures, such asmicrobiological culture,
histological examination of biopsy specimens, and radiographic
evidence
that can be used to aid in the diagnosis of Invasive Aspergillosis.
Twice weekly monitoring of neutropenic patients is often recommended
in
the peer-reviewed literature to obtain maximum diagnostic utility of
the assay.
Test
Limitations:
A negative test result cannot rule out the diagnosis of Invasive
Aspergillosis.
Patients at risk for Invasive Aspergillosis should be tested twice per
week.
If a positive result is obtained, a second specimen should be
collected and sent for testing immediately.
The performance of the Aspergillus Galactomannan EIA has not been
evaluated with neonatal specimens.
The Aspergillus Galactomannan EIA may exhibit reduced detection in
patients with chronic granulomatous disease and Job's Syndrome.
The concomitant use of mold-active, anti fungal therapy in some
patients with Invasive Aspergillosis may result in reduced sensitivity
of the Aspergillus Galactomannan EIA.
There are reports in the literature of positive galactomannan test
results in patients receiving piperacillin/tazobactam, therefore,
results in these patients should be interpreted with caution and
confirmed with other diagnostic methods.
There are reports in the literature of positive galactomannan test
results in patients with intestinal mucositis caused by chemotherapy
and irradiation, which allows for extra absorption of dietary
galactomannan.
Methodology:
Enzyme Immunoassay
CPT Code:
87305
